BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Damsky W, Peterson D, Ramseier J, Al-Bawardy B, Chun H, Proctor D, Strand V, Flavell RA, King B. The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases. J Allergy Clin Immunol 2021;147:814-26. [PMID: 33129886 DOI: 10.1016/j.jaci.2020.10.022] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Cui L, Ma R, Cai J, Guo C, Chen Z, Yao L, Wang Y, Fan R, Wang X, Shi Y. RNA modifications: importance in immune cell biology and related diseases. Signal Transduct Target Ther 2022;7:334. [PMID: 36138023 DOI: 10.1038/s41392-022-01175-9] [Reference Citation Analysis]
2 Selvaraj V, Finn A, Lal A, Khan MS, Dapaah-Afriyie K, Carino GP. Baricitinib in hospitalised patients with COVID-19: A meta-analysis of randomised controlled trials. EClinicalMedicine 2022;49:101489. [PMID: 35677732 DOI: 10.1016/j.eclinm.2022.101489] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
3 Basheer F, Bulleeraz V, Ngo VQT, Liongue C, Ward AC. In vivo impact of JAK3 A573V mutation revealed using zebrafish. Cell Mol Life Sci 2022;79:322. [PMID: 35622134 DOI: 10.1007/s00018-022-04361-8] [Reference Citation Analysis]
4 Bond M, Tomelleri A, Buttgereit F, Matteson EL, Dejaco C. Looking ahead: giant-cell arteritis in 10 years time. Therapeutic Advances in Musculoskeletal 2022;14:1759720X2210963. [DOI: 10.1177/1759720x221096366] [Reference Citation Analysis]
5 Waibel M, Thomas HE, Wentworth JM, Couper JJ, Macisaac RJ, Cameron FJ, So M, Krishnamurthy B, Doyle MC, Kay TW. Investigating the efficacy of baricitinib in new onset type 1 diabetes mellitus (BANDIT)—study protocol for a phase 2, randomized, placebo controlled trial. Trials 2022;23. [DOI: 10.1186/s13063-022-06356-z] [Reference Citation Analysis]
6 Yu X, Lv J, Wu J, Chen Y, Chen F, Wang L. The autoimmune encephalitis-related cytokine TSLP in the brain primes neuroinflammation by activating the JAK2-NLRP3 axis. Clin Exp Immunol 2022;207:113-22. [PMID: 35020848 DOI: 10.1093/cei/uxab023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Klein B, Treudler R, Simon JC. JAK-Inhibitoren in der Dermatologie - kleine Moleküle, große Wirkung? Übersicht über Wirkmechanismus, Studienergebnisse und mögliche unerwünschte Wirkungen. J Dtsch Dermatol Ges 2022;20:19-25. [PMID: 35040564 DOI: 10.1111/ddg.14668_g] [Reference Citation Analysis]
8 Rommasi F, Nasiri MJ, Mirsaeidi M. Immunomodulatory agents for COVID-19 treatment: possible mechanism of action and immunopathology features. Mol Cell Biochem 2022. [PMID: 35013850 DOI: 10.1007/s11010-021-04325-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Klein B, Treudler R, Simon JC. JAK-inhibitors in dermatology - small molecules, big impact? Overview of the mechanism of action, previous study results and potential adverse effects. J Dtsch Dermatol Ges 2021. [PMID: 34962052 DOI: 10.1111/ddg.14668] [Reference Citation Analysis]
10 Tomelleri A, van der Geest KSM, Sebastian A, van Sleen Y, Schmidt WA, Dejaco C, Dasgupta B. Disease stratification in giant cell arteritis to reduce relapses and prevent long-term vascular damage. The Lancet Rheumatology 2021;3:e886-95. [DOI: 10.1016/s2665-9913(21)00277-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
11 Ingrasci G, Lipman ZM, Yosipovitch G. When topical therapy of atopic dermatitis fails: a guide for the clinician. Expert Rev Clin Immunol 2021;:1-12. [PMID: 34720031 DOI: 10.1080/1744666X.2021.2000390] [Reference Citation Analysis]
12 Murphy MJ, Gruenstein D, Wang A, Peterson D, Levitt J, King B, Damsky W. Treatment of Persistent Erythema Multiforme With Janus Kinase Inhibition and the Role of Interferon Gamma and Interleukin 15 in Its Pathogenesis. JAMA Dermatol 2021. [PMID: 34757416 DOI: 10.1001/jamadermatol.2021.4084] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Hassoun D, Malard O, Barbarot S, Magnan A, Colas L. Type 2 immunity-driven diseases: Towards a multidisciplinary approach. Clin Exp Allergy 2021. [PMID: 34617355 DOI: 10.1111/cea.14029] [Reference Citation Analysis]
14 Hadjadj J, Frémond ML, Neven B. Emerging Place of JAK Inhibitors in the Treatment of Inborn Errors of Immunity. Front Immunol 2021;12:717388. [PMID: 34603291 DOI: 10.3389/fimmu.2021.717388] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
15 Abe M, Iizuka H, Nemoto‐hasebe I, Nemoto O, Toyama H, Ohashi‐doi K, Kabashima K. Clinical effect of delgocitinib 0.5% ointment on atopic dermatitis eczema intensity and skin barrier function. J Cutan Immunol Allergy. [DOI: 10.1002/cia2.12213] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Beurier P, Ricard L, Eshagh D, Malard F, Siblany L, Fain O, Mohty M, Gaugler B, Mekinian A. TFH cells in systemic sclerosis. J Transl Med 2021;19:375. [PMID: 34461933 DOI: 10.1186/s12967-021-03049-0] [Reference Citation Analysis]
17 Meher BR, Mohanty RR, Padhy BM. Efficacy and safety of abrocitinib for the treatment of moderate-to-severe atopic dermatitis: a meta-analysis of randomized clinical trials. J Dermatolog Treat 2021;:1-9. [PMID: 34315323 DOI: 10.1080/09546634.2021.1961997] [Reference Citation Analysis]
18 Lee H, Lee DH, Oh JH, Chung JH. Skullcapflavone II Suppresses TNF-α/IFN-γ-Induced TARC, MDC, and CTSS Production in HaCaT Cells. Int J Mol Sci 2021;22:6428. [PMID: 34208434 DOI: 10.3390/ijms22126428] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Chaichian Y, Wallace DJ. Innovative Trials and New Opportunities in SLE. Rheum Dis Clin North Am 2021;47:481-99. [PMID: 34215375 DOI: 10.1016/j.rdc.2021.04.010] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Casal-dominguez M, Pinal-fernandez I, Mammen AL. Inhibiting Interferon Pathways in Dermatomyositis: Rationale and Preliminary Evidence. Curr Treat Options in Rheum 2021;7:258-71. [DOI: 10.1007/s40674-021-00182-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Galvez-Llompart M, Ocello R, Rullo L, Stamatakos S, Alessandrini I, Zanni R, Tuñón I, Cavalli A, Candeletti S, Masetti M, Romualdi P, Recanatini M. Targeting the JAK/STAT Pathway: A Combined Ligand- and Target-Based Approach. J Chem Inf Model 2021;61:3091-108. [PMID: 33998810 DOI: 10.1021/acs.jcim.0c01468] [Reference Citation Analysis]
22 Wijaya I, Andhika R, Huang I, Purwiga A, Budiman KY, Bashari MH, Reniarti L, Roesli RMA. The use of Janus Kinase inhibitors in hospitalized patients with COVID-19: Systematic review and meta-analysis. Clin Epidemiol Glob Health 2021;11:100755. [PMID: 33969237 DOI: 10.1016/j.cegh.2021.100755] [Cited by in Crossref: 3] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
23 Takanashi S, Kaneko Y, Takeuchi T. Tofacitinib in interstitial lung disease complicated with anti-MDA5 antibody-positive dermatomyositis: A literature review. Mod Rheumatol 2021;:1-7. [PMID: 33769925 DOI: 10.1080/14397595.2021.1906505] [Reference Citation Analysis]
24 Reddig A, Voss L, Guttek K, Roggenbuck D, Feist E, Reinhold D. Impact of Different JAK Inhibitors and Methotrexate on Lymphocyte Proliferation and DNA Damage. J Clin Med 2021;10:1431. [PMID: 33916057 DOI: 10.3390/jcm10071431] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
25 Kotyla PJ, Engelmann M, Giemza-Stokłosa J, Wnuk B, Islam MA. Thromboembolic Adverse Drug Reactions in Janus Kinase (JAK) Inhibitors: Does the Inhibitor Specificity Play a Role? Int J Mol Sci 2021;22:2449. [PMID: 33671049 DOI: 10.3390/ijms22052449] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
26 Del Papa N, Minniti A, Lorini M, Carbonelli V, Maglione W, Pignataro F, Montano N, Caporali R, Vitali C. The Role of Interferons in the Pathogenesis of Sjögren's Syndrome and Future Therapeutic Perspectives. Biomolecules 2021;11:251. [PMID: 33572487 DOI: 10.3390/biom11020251] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
27 Giles H, Pratt G. Janus kinase 2 (JAK2) inhibitors in the treatment of multiple myeloma: modulating the myeloma immune microenvironment. Br J Haematol 2021;192:420-2. [PMID: 33341927 DOI: 10.1111/bjh.17277] [Reference Citation Analysis]